Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013, Article ID 274986, 5 pages
http://dx.doi.org/10.1155/2013/274986
Research Article

The Effect of Simvastatin on Glucose Homeostasis in Streptozotocin Induced Type 2 Diabetic Rats

1School of Medicine, Shandong University, Jinan, Shandong 250013, China
2Department of Medicine, Jinan Central Hospital Shandong University, Jinan, Shandong 250013, China

Received 15 October 2012; Revised 1 January 2013; Accepted 21 January 2013

Academic Editor: Syed Ibrahim Rizvi

Copyright © 2013 Lulu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar
  2. Cholesterol Treatment Trialists' (CTT) Collaborators, “Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis,” The Lancet, vol. 371, no. 9607, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. K. Liao, “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” Current Atherosclerosis Reports, vol. 11, no. 4, pp. 243–244, 2009. View at Google Scholar
  4. C. P. Cannon, B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald, “Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy,” Journal of the American College of Cardiology, vol. 48, no. 3, pp. 438–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kumai, N. Matsumoto, Y. Koitabashi et al., “Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels,” Current Medicinal Chemistry, vol. 3, no. 3, pp. 195–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Ma, M.-H. Chang, L. Tien, Y.-S. Liou, and G.-P. Jong, “The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study,” Drugs and Aging, vol. 29, no. 1, pp. 45–51, 2012. View at Publisher · View at Google Scholar
  7. A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, and T. Rönnemaa, “Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial,” JAMA, vol. 287, no. 5, pp. 598–605, 2002. View at Google Scholar · View at Scopus
  8. C. Ohmura, H. Watada, T. Hirose, Y. Tanaka, and R. Kawamori, “Acute onset and worsening of diabetes concurrent with administration of statins,” Endocrine Journal, vol. 52, no. 3, pp. 369–372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. H. Gannagé-Yared, R. R. Azar, M. Amm-Azar et al., “Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients,” Metabolism, vol. 54, no. 7, pp. 947–951, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. K. K. Koh, M. J. Quon, S. H. Han et al., “Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1649–1653, 2005. View at Publisher · View at Google Scholar
  11. K. K. Kwang, M. J. Quon, H. H. Seung et al., “Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients,” Circulation, vol. 110, no. 24, pp. 3687–3692, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Güçlü, B. Özmen, Z. Hekimsoy, and C. Kirmaz, “Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome,” Biomedicine and Pharmacotherapy, vol. 58, no. 10, pp. 614–618, 2004. View at Publisher · View at Google Scholar
  13. K. Okada, N. Maeda, K. Kikuchi, M. Tatsukawa, Y. Sawayama, and J. Hayashi, “Pravastatin improves insulin resistance in dyslipidemic patients,” Journal of Atherosclerosis And thrombosis, vol. 12, no. 6, pp. 322–329, 2005. View at Google Scholar · View at Scopus
  14. M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi, and T. Yada, “Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control,” Diabetologia, vol. 49, no. 8, pp. 1881–1892, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Ginter and V. Simko, “Statins: the drugs for the 21st century?” Bratislavské Lekárske Listy, vol. 110, no. 10, pp. 664–668, 2009. View at Google Scholar · View at Scopus
  16. M. Epstein and V. M. Campese, “Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function,” American Journal of Kidney Diseases, vol. 45, no. 1, pp. 2–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Malcolm, H. Meggison, and R. Sigal, “Prevention of cardiovascular events in diabetes,” Clinical Evidence, no. 10, pp. 690–714, 2003. View at Google Scholar · View at Scopus
  18. C. A. Lalli, J. R. Pauli, P. O. Prada et al., “Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet,” Metabolism, vol. 57, no. 1, pp. 57–65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Takagi, M. Matsuda, M. Abe et al., “Effect of pravastatin on the development of diabetes and adiponectin production,” Atherosclerosis, vol. 196, no. 1, pp. 114–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Sugiyama, H. Fukushima, K. Kugiyama et al., “Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease,” Atherosclerosis, vol. 194, no. 2, pp. e43–e51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Costa, R. Casamitjana, E. Casals et al., “Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose,” Diabetic Medicine, vol. 20, no. 9, pp. 743–745, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Szendroedi, C. Anderwald, M. Krssak et al., “Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients,” Diabetes Care, vol. 32, no. 2, pp. 209–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Sukhija, S. Prayaga, M. Marashdeh et al., “Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients,” Journal of Investigative Medicine, vol. 57, no. 3, pp. 495–499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Sattar, D. Preiss, H. M. Murray et al., “Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials,” The Lancet, vol. 375, no. 9716, pp. 735–742, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar
  27. C. Bianchi, G. Penno, R. Miccoli, and S. Del Prato, “Blood glucose control and coronary heart disease,” Herz, vol. 35, no. 3, pp. 148–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. L. H. Chamberlain, “Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes,” FEBS Letters, vol. 507, no. 3, pp. 357–361, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Mabuchi, T. Higashikata, M. Kawashiri et al., “Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients,” Journal of Atherosclerosis and Thrombosis, vol. 12, no. 2, pp. 111–119, 2005. View at Google Scholar
  30. J. Sasaki, M. Iwashita, and S. Kono, “Statins: beneficial or adverse for glucose metabolism,” Journal of Atherosclerosis and Thrombosis, vol. 13, no. 3, pp. 123–129, 2006. View at Google Scholar · View at Scopus
  31. C. Nielson, T. Lange, and N. Hadjokas, “Blood glucose and coronary artery disease in nondiabetic patients,” Diabetes Care, vol. 29, no. 5, pp. 998–1001, 2006. View at Publisher · View at Google Scholar · View at Scopus